Table 1.

Characteristics of the Cohorts Included in a Pooled Analysis of Vitamin E Intake and Amyotrophic Lateral Sclerosis Risk, 1976–2005

Study	Follow-up		Baseline Cohort Sizea	No. of ALS Cases	Baseline Age Range, Years	Vitamin E Supplement Use, %	Dietary Vitamin E Intake, mg/dayb
	Start	End					Median	10%–90% Range
Health Professionals Follow-up Study	1986	2004	49,845	56	39–79	45.6	9.8	7.3–13.7
NHS (1980)	1980	1990	92,222	19	33–66	38.4	6.8	5.0–9.6
NHS (1990)	1990	2004	78,589	45	43–76	43.1	7.9	6.0–10.7
CPS-II Nutrition Cohortc
Men	1992	2004	77,444	106	41–93	39.1	8.7	5.0–14.2
Women	1992	2004	88,218	73	40–87	49.6	7.4	3.9–14.9
Multiethnic Cohort Study
Men	1993–1997	2005	92,677	66	41–78	50.4	8.7	4.3–19.4
Women	1993–1997	2005	113,558	45	42–78	45.6	7.7	3.9–17.5
NIH-AARP Diet and Health Study
Men	1995–1996	2005	325,411	280	50–72	61.0	7.0	3.9–12.6
Women	1995–1996	2005	216,171	115	50–72	70.6	5.9	3.3–10.8
Total			1,055,546d	805

Abbreviations: ALS, amyotrophic lateral sclerosis; CPS-II, Cancer Prevention Study II; NHS, Nurses’ Health Study; NIH, National Institutes of Health.

^aCohort size after applying study-specific exclusion criteria and then excluding participants with log-transformed energy intake values beyond 3 standard deviations from the study-specific mean.

^bTo convert mg to IU, multiply by 1.49.

^cForty-seven participants with ALS in the CPS-II Nutrition Cohort were included in our previous study of vitamin E supplement use and ALS (13) in the parent CPS-II baseline cohort (over 1 million participants enrolled in 1982).

^d NHS (1980) and NHS (1990) were the same participants followed for ALS during different time periods. Therefore, the total number of participants does not include NHS (1990), which is a subset of NHS (1980).